Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis
Introduction: Rituximab-based B-cell depletion (BCD) therapy is effective in refractory
rheumatoid arthritis (RA) and although used to treat patients with refractory systemic lupus
erythematosus (SLE) in routine clinical practice, rituximab failed to meet the primary
endpoints in two large randomised controlled trials (RCTs) of non-renal (EXPLORER) and
renal (LUNAR) SLE. Areas covered: We review how BCD could be improved to achieve
better clinical responses in RA and SLE. Insights into the variability in clinical response to …
rheumatoid arthritis (RA) and although used to treat patients with refractory systemic lupus
erythematosus (SLE) in routine clinical practice, rituximab failed to meet the primary
endpoints in two large randomised controlled trials (RCTs) of non-renal (EXPLORER) and
renal (LUNAR) SLE. Areas covered: We review how BCD could be improved to achieve
better clinical responses in RA and SLE. Insights into the variability in clinical response to …
Abstract
Introduction: Rituximab-based B-cell depletion (BCD) therapy is effective in refractory rheumatoid arthritis (RA) and although used to treat patients with refractory systemic lupus erythematosus (SLE) in routine clinical practice, rituximab failed to meet the primary endpoints in two large randomised controlled trials (RCTs) of non-renal (EXPLORER) and renal (LUNAR) SLE.
Areas covered: We review how BCD could be improved to achieve better clinical responses in RA and SLE. Insights into the variability in clinical response to BCD in RA and SLE may help develop new therapeutic strategies. To this end, a literature search was performed using the following terms: rheumatoid arthritis, systemic erythematosus lupus, rituximab and B-cell depletion.
Expert commentary: Poor trial design may have, at least partly, contributed to the apparent lack of response to BCD in the two RCTs of patients with SLE. Enhanced B-cell depletion and/or sequential therapy with belimumab may improve clinical response at least in some patients with SLE
Taylor & Francis Online以上显示的是最相近的搜索结果。 查看全部搜索结果